Free Trial

MiNK Therapeutics Q2 2023 Earnings Report

MiNK Therapeutics logo
$9.09 +0.06 (+0.61%)
As of 12:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MiNK Therapeutics EPS Results

Actual EPS
-$1.80
Consensus EPS
-$1.90
Beat/Miss
Beat by +$0.10
One Year Ago EPS
-$1.80

MiNK Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MiNK Therapeutics Announcement Details

Quarter
Q2 2023
Time
Before Market Opens

Conference Call Resources

Remove Ads

MiNK Therapeutics Earnings Headlines

HC Wainwright Cuts Earnings Estimates for MiNK Therapeutics
Brokers Issue Forecasts for INKT Q1 Earnings
The unusual signal flashing green again
Something fascinating happened in April... While a lot of Wall Street institutions were opening new positions in a falling stock, something different showed up on my screen. A special set of candles had just turned green - signaling the kind of momentum surge I'd seen only a handful of times before. What happened next? The stock soared 45% on the underlying stock in just a few weeks and 227% for anyone who traded the options. Naturally, there would have been smaller wins and those that would not have worked out, but this wasn't some penny stock or crypto play… It was ARM Holdings - a major semiconductor player that had just shed 9% of its value.
What is William Blair's Estimate for INKT Q1 Earnings?
See More MiNK Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MiNK Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MiNK Therapeutics and other key companies, straight to your email.

About MiNK Therapeutics

MiNK Therapeutics (NASDAQ:INKT), a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

View MiNK Therapeutics Profile

More Earnings Resources from MarketBeat